European Urology

Editorial Board

6 July 2009 | page i

Contents

6 July 2009 | pages v - viii

  Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer

Michael J. Morris, Daisy Huang, William K. Kelly, Susan F. Slovin, Ryan D. Stephenson, Caitlin Eicher, Anthony Delacruz, Tracy Curley, Lawrence H. Schwartz and Howard I. Scher

3 April 2009 | pages 237 - 244

Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach

Robert A. Gardiner, Christopher Sweeney and Wayne D. Tilley

22 April 2009 | pages 245 - 246

  An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, Martin Friedrich, Susanne Krege, Erkki Rintala, Eduardo Solsona, Savino M. Di Stasi and J. Alfred Witjes

24 April 2009 | pages 247 - 256

Is Intravesical Bacillus Calmette-Guérin Better than Mitomycin for Intermediate-Risk Bladder Cancer?

Guido Dalbagni

3 May 2009 | pages 257 - 258

Rebuttal from Authors re: Guido Dalbagni. Is Intravesical Bacillus Calmette-Guérin Better than Mitomycin for Intermediate-Risk Bladder Cancer? Eur Urol 2009;56:257–8

Per-Uno Malmström and Richard J. Sylvester

26 May 2009 | pages 258 - 259

  Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up

Riikka Järvinen, Eero Kaasinen, Anna Sankila and Erkki Rintala FinnBladder Group.

16 April 2009 | pages 260 - 265

Bacillus Calmette-Guérin versus Mitomycin C for the Treatment of Intermediate-Risk Non–Muscle-Invasive Bladder Cancer: The Debate Continues

Richard J. Sylvester

3 May 2009 | pages 266 - 268

Rebuttal from Authors re: Richard J. Sylvester. Bacillus Calmette-Guérin versus Mitomycin C for the Treatment of Intermediate-Risk Non–Muscle-Invasive Bladder Cancer: The Debate Continues. Eur Urol 2009;56:266–8

Riikka Järvinen, Eero Kaasinen, Anna Sankila and Erkki Rintala

26 May 2009 | pages 268 - 269